| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3849164 | American Journal of Kidney Diseases | 2012 | 8 Pages |
Abstract
Dalteparin and tinzaparin significantly accumulate in HD patients at therapeutic doses. “Bridging therapy” with LMWHs at therapeutic doses in HD patients who require temporary interruption of warfarin therapy has the potential for complications and is of uncertain benefit. Other anticoagulation strategies, including no bridging therapy or intravenous heparin, need comparative evaluation in this unique patient population.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Marc A. MD, Tim PhD, Martin MD, Margit PhD, Philip S. MD, Brendan MD, Greg MD,